Article
SARS-CoV-2 affects renal function, and some patients have been known to develop acute kidney injury (AKI). Kidney patients are also at greater risk from coronavirus. On June 5 at 3.30 pm CEST, experts will convene in a special online Zoom session of the ERA-EDTA (European Renal Association and European Dialysis and Transplant Association). to discuss the relationship between coronavirus and kidney function.
tashatuvango@AdobeStock_124119605
SARS-CoV-2 affects renal function, and some patients have been known to develop acute kidney injury (AKI). Kidney patients are also at greater risk from coronavirus. On June 5 at 3.30 pm CEST, experts will convene in a special online Zoom session of the ERA-EDTA (European Renal Association and European Dialysis and Transplant Association). to discuss the relationship between coronavirus and kidney function.
The Congress of the ERA-EDTA is Europe´s biggest congress on nephrology and renal replacement therapy. More than 8,000 participants sharing their knowledge and discussing the latest research findings are expected. This year, the Congress will continue as planned from June 6-9, 2020, but in a fully virtual form.
A day before the Congress, on June 5, at 3.30 pm CEST, we extend a cordial invitation to a ZOOM Press Conference on Corona and the Kidneys. Various international experts will report on their experience during the corona crisis and will discuss the latest research findings.
Program of the Press Conference
Are dialysis patients at particular risk? The Italian experience
Mario Gennaro Cozzolino
Dialysis and mortality in Spain
Maria Jose Soler Romeo
Prognosis and risk factors for mortality in patients on kidney replacement therapy with COVID-19: The ERACODA Study
Luuk Hilbrands
AKI and ESKD in severe COVID-19: pathology, management, outcome. The German experience
Elion Hoxha (t.b.c.)
To attend the Press Conference, please send an email with your contact details and details of the medium for which you are working to press@era-edta.org. After you register, you will be sent the link to the conference.
ERA-EDTA Press Office
Dr. Bettina Albers
Tel. +49 3643 7764-23
Mobile +49 174 2165629
email: press@era-edta.org
FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia
FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia
2 Commerce Drive
Cranbury, NJ 08512